

## Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome

Sarah M. Nielsen, Lindsay Rhodes, Ignacio Blanco, Wendy K. Chung, Charis Eng, Eamonn R. Maher, Stéphane Richard, and Rachel H. Giles

### A B S T R A C T

Von Hippel-Lindau disease (VHL) is one of the most common inherited neoplasia syndromes and is characterized by highly vascular tumors of the eyes, brain, and spine, as well as benign and malignant tumors and/or cysts of the kidneys, adrenal medullae and sympathetic paraganglia, endolymphatic sac, epididymis, and broad ligament. Since the discovery of the *VHL* gene in 1993, more than 900 families with VHL have been identified and examined. Genetic testing for *VHL* is widely available and will detect a disease-causing mutation in rate 95% to 100% of individuals who have a clinical diagnosis of VHL, making it the standard of care for diagnosis of VHL. Furthermore, genetic testing for *VHL* is indicated in some individuals with seemingly sporadic VHL-related tumor types, as  $\leq 10\%$  of pheochromocytoma or early-onset renal cell carcinoma and  $\leq 40\%$  of CNS hemangioblastoma harbor germline *VHL* mutations without a family history or additional features of VHL disease. The majority of *VHL* mutations are private, but there are also well-characterized founder mutations. VHL is a complex, multiorgan disease that spans the breadth of oncology subspecialties, and, as such, providers in these subspecialties should be aware of when to consider a diagnosis of VHL, when to refer a patient to a genetics specialist for consideration of gene testing, and, perhaps most importantly, how to communicate this sensitive information in an age-appropriate manner to at-risk families. This review will provide state-of-the-art information regarding the genetics of VHL and will serve as a key reference for nongenetics professionals who encounter patients with VHL.

*J Clin Oncol* 34:2172-2181. © 2016 by American Society of Clinical Oncology

### INTRODUCTION

Von Hippel-Lindau disease (VHL) is an inherited multiple-neoplasia syndrome that is characterized by highly vascular tumors of the eyes, brain, and spine (retinal and CNS hemangioblastomas [HBs]), as well as benign and malignant tumors and/or cysts of the kidneys (clear cell renal cell carcinoma [RCC]), adrenal glands and sympathetic paraganglia (pheochromocytoma [PCC] and paraganglioma [PGL]), pancreas (cysts and cystadenomas or pancreatic neuroendocrine tumors), endolymphatic sac (endolymphatic sac tumors [ELSTs]), epididymis (epididymal cysts and cystadenomas), and broad ligament (broad ligament and mesosalpinx cystadenoma).<sup>1-4</sup> Since the first description of the disease in 1926<sup>5</sup> and the discovery of the *VHL* gene > 60 years later,<sup>6</sup> more than 900 families worldwide with VHL have been identified and examined.<sup>7,8</sup>

A timely review of the genetics of VHL is warranted because genetics is becoming increasingly integrated into health care in the name of

personalized or precision medicine. As such, health care providers must now, more than ever, understand the sensitive and unique nature of communicating genetic information to patients. This is especially true in the field of oncology, for which both somatic and germline genetic testing is becoming a standard part of oncologic work-up and clinical care. In the context of VHL, it is important to consider the sensitive nature of presymptomatic testing of children as well as unexpected (incidental) VHL diagnoses as a result of incorporation of multigene next-generation sequencing panels into clinical practice for sporadic VHL-associated tumors, namely RCC and PCC and/or PGL. Other special considerations in VHL include preconception counseling, including pregnancy-related risks, and the burden of extensive clinical screening.

### CLINICAL DIAGNOSIS AND *VHL* GENE

A VHL diagnosis is established in an individual with a family history of VHL when he or she

Sarah M. Nielsen and Lindsay Rhodes, The University of Chicago, Chicago, IL; Ignacio Blanco, Hospital Universitari Germans Trias i Pujol, UAB - Universitat Autònoma de Barcelona, Barcelona, Spain; Wendy K. Chung, Columbia University, New York, NY; Charis Eng, Cleveland Clinic; Eamonn R. Maher, Western Reserve University School of Medicine, Cleveland, OH; Eamonn R. Maher, University of Cambridge and Cambridge NIHR Biomedical Research Centre, Cambridge, United Kingdom; Stéphane Richard, Réseau National pour Cancers Rares de l'Adulte PREDIR, INCa/AP-HP, Hôpital Bicêtre, Le Kremlin Bicêtre; Stéphane Richard, INSERM U1186, Gustave Roussy Cancer Campus, Villejuif, France; Rachel H. Giles, University Medical Center Utrecht, Regenerative Medicine Center Utrecht, Utrecht; and Rachel H. Giles, Dutch VHL Patient Organization, Gouda, the Netherlands.

Published online ahead of print at [www.jco.org](http://www.jco.org) on April 25, 2016.

Corresponding author: Sarah Nielsen, MS, CGC, University of Chicago Medicine & Biological Sciences, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637; e-mail: [sn Nielsen@medicine.bsd.uchicago.edu](mailto:sn Nielsen@medicine.bsd.uchicago.edu).

© 2016 by American Society of Clinical Oncology

0732-183X/16/3418w-2172w/\$20.00

DOI: 10.1200/JCO.2015.65.6140

presents with a single characteristic VHL-related tumor, for example, retinal or cerebellar HB, RCC, etc. In the absence of a family history of VHL, a diagnosis requires two or more retinal or cerebellar HB, or one HB and a visceral tumor, excluding epididymal and renal cysts which are common in the general population.<sup>1,9-11</sup>

The VHL tumor suppressor gene (*VHL*) was mapped to 3p25-26 in 1993.<sup>6</sup> Individuals with the hereditary form of these tumors inherit a single mutant *VHL* allele, and tumor development occurs when the second wild-type copy is spontaneously lost or inactivated. This second hit can occur through a variety of mechanisms, including point mutations, deletions, or promoter hypermethylation.<sup>12</sup> As with many predisposition genes that cause rare inherited cancer syndromes, somatic loss of function of *VHL* occurs in sporadic cancers.<sup>13-15</sup> Indeed, inactivation of *VHL* is a critical driver of nearly all clear-cell RCC,<sup>16,17</sup> approximately 40% of sporadic CNS HB, and 10% of sporadic PCC.<sup>18-21</sup>

### MOLECULAR BIOLOGY OF VHL

More than two decades of research has implicated VHL protein (pVHL) in transcriptional regulation, apoptosis, extracellular matrix formation, and ubiquitinylation of specific targets.<sup>21</sup> In particular, the role of pVHL in the adaptive cellular response to hypoxia has been robustly investigated; pVHL regulates hypoxia-inducible genes via the targeted ubiquitinylation and degradation of the  $\alpha$ -subunits of hypoxia-inducible factor transcription factors (HIF-1 $\alpha$ , HIF-2 $\alpha$ , and HIF-3 $\alpha$ ).

pVHL binds to elongin C, which forms a complex with elongin B, cullin-2, and Rbx1. This complex catalyzes the poly-ubiquitinylation of specific proteins and targets them for proteosomal degradation. Under normoxic conditions, HIF $\alpha$  subunits are hydroxylated by prolyl hydroxylases, which is a reaction that requires oxygen. pVHL protein then binds to hydroxylated HIF $\alpha$ , targeting it for degradation by its attached destruction complex. In the absence of oxygen or functional pVHL, HIF $\alpha$  subunits are stabilized, accumulate, and translocate to the nucleus where HIF $\alpha$  forms heterodimers with HIF $\beta$  to activate the transcription of dozens of hypoxia-inducible genes, for example, *VEGF*, *EPO*, *TGF $\alpha$* , *PDGF $\beta$* .<sup>21</sup> *VHL* mutant cells experience pseudohypoxia and shift metabolism to glycolysis even in the presence of oxygen, a process referred to as the Warburg effect. In fact, our ability to better manage patients with nonfamilial, advanced RCC and the surgical management guidelines of small renal masses have been largely driven by a better understanding of VHL and the consequent biochemical alterations that underlie these tumors, in particular, first-line vascular endothelial growth factor (VEGF)-targeting agents.<sup>22</sup>

Pathogenic variants in *VHL* either reduce expression, that is, deletions, frameshifts, nonsense variants, and splice site variants, or lead to the expression of an abnormal protein, that is, pathogenic missense variants. The type of VHL that results from a pathogenic missense variant depends on its effect on the three-dimensional structure of the protein.<sup>23</sup> Pathogenic variants in *VHL* cause misfolding and subsequent chaperonin-mediated breakdown.<sup>24</sup> Pathogenic missense variants that destabilize packing of the  $\alpha$ -helical domains, decrease the stability of the  $\alpha$ - $\beta$  domain

interface, interfere with binding of elongin C and HIF $\alpha$ , or disrupt hydrophobic core residues result in loss of HIF regulation. Furthermore, mutant pVHL may predispose patients to pheochromocytoma by altering the molecular regulation of apoptosis of sympathoadrenal precursor cells during development.<sup>25</sup>

HIF-independent pVHL functions have added greater breadth to the understanding of the pathophysiology of VHL. For example, cyst formation in patients with VHL has been linked microtubule-based organelles called primary cilia. pVHL directs microtubule orientation and subsequent stability.<sup>26-28</sup> pVHL also regulates primary cilia via both HIF- and microtubule-independent functions.<sup>29-31</sup> Furthermore, genetic instability in tumors is driven by VHL loss.<sup>32</sup>

pVHL has been shown to mediate transcriptional regulation of nuclear factor- $\kappa$ B,<sup>33</sup> Rbp1 large subunit of RNA polymerase complex II,<sup>34,35</sup> p53 tumor suppressor,<sup>36</sup> p400 chromatin remodeling factor,<sup>37</sup> and JunB transcription factor via protein kinase C<sup>25,38</sup>; however, pVHL also plays an important transcription-independent role in the regulation of extracellular matrix (ECM) and the microtubule cytoskeleton. pVHL is involved in the correct formation and turnover of the ECM<sup>39</sup> by interacting with collagen IV<sup>40</sup> and fibronectin.<sup>41</sup> *Caenorhabditis elegans vhl-1* knockout worms also displayed genetic evidence for defects in ECM formation.<sup>42</sup> Furthermore, the activity of enzymes involved in the degradation and remodeling of ECM, matrix metalloproteinase (MMP)-2, and MMP-9<sup>43</sup> is increased in VHL-mutant cells, and HIF-2 $\alpha$  induces the expression of membrane type 1 MMP. As endothelial cells require pVHL for correct vascular patterning and maintenance of vascular integrity during development,<sup>44</sup> loss of pVHL function causes both HIF-independent and -dependent defects in ECM that may promote angiogenesis, invasion, and metastasis of tumor cells.<sup>39</sup>

Development of malignant disease after biallelic inactivation of *VHL* has only been adequately addressed in the context of RCC. Several RCCs sequenced in two patients with VHL revealed clonally independent and distinct secondary events that all converge on the PI3K-AKT-mTOR signaling pathway and are not characterized by inactivating mutations in p53, similar to sporadic RCCs in the general public.<sup>45</sup> Overall, there was limited evidence of intratumor heterogeneity in patients with VHL, although the number was small and requires independent validation.

### ROLE OF GENETIC TESTING, MUTATION FREQUENCY, AND SPECTRA

The role of genetic testing in VHL is to confirm or exclude a diagnosis in at-risk relatives from established families with VHL, individuals with suspected clinical diagnoses, or individuals with atypical presentation or moderate suspicion, keeping in mind that failure to find a disease-causing mutation does not rule out a clinical diagnosis in the second scenario.

Among the more than 900 families in whom VHL has been identified, approximately 200 distinct mutations have been found.<sup>7,8,46</sup> The mutation spectrum includes missense (52% of patients), frameshift (13%), nonsense (11%), large and complete deletions (11%), in-frame deletions or insertions (6%), and splice site (7%).<sup>7</sup> Almost 100% of individuals that meet classic VHL

criteria with multiorgan involvement carry identifiable germline *VHL* mutations, but mutation detection rate decreases to 24% in those who meet criteria with limited *VHL* manifestations, and to 3.3% in those with *VHL*-associated tumors who do not meet diagnostic criteria.<sup>47</sup> Unexpected germline *VHL* mutations can be found in patients who have seemingly sporadic *VHL*-type tumors. *VHL* germline mutations occur in 30% to 50% of patients with retinal HB, 4% to 40% of patients with CNS HB, 20% of patients with ELST, 3% to 11% of patients with PCC, and 1% to 2% of patients with RCC.<sup>1,48-55</sup> These observations underlie guidelines that suggest genetics evaluation when certain tumors or clinical features are present. Referral to genetics professionals for consideration of testing (Table 1) has been suggested for individuals with simplex cases of retinal or CNS HB, PCC, or ELST, as well as clear-cell RCC with any of the following features: diagnosed at an age  $\leq$  46 years, bilateral or multifocal tumors, or one or more close relatives with clear-cell RCC.<sup>56</sup> Whereas other groups have suggested that, in addition to the above, genetic evaluation is warranted for individuals with more than one of the following: pancreatic cystadenoma, pancreatic neuroendocrine tumor, and epididymal and adnexal cystadenoma.<sup>57</sup>

### VHL GENE TESTING

*VHL* genetic testing is available at multiple laboratories worldwide (Table 2). Sanger sequencing of the coding region, along with deletion/duplication analysis, is the gold standard for analyzing the *VHL* gene and it results in a 95% to 100% detection rate, though mosaicism may cause false-negative test results.<sup>59,60</sup> Multiplex ligation-dependent probe amplification is used for detecting partial and complete gene deletions/duplications.<sup>47,61</sup>

When there is a high prior probability of *VHL* mutation, single gene testing is appropriate; however, when the genetic differential diagnosis is large, next-generation sequencing multigene panels should be considered in the setting of genetic counseling. This technology is often used for testing seemingly sporadic PCC and/or PGL or familial and early-onset RCC to determine if there is an inherited component. Thus, referral for genetics evaluation should be considered for RCC diagnosed at an age  $\leq$  46

**Table 1.** Indications For Consideration of Genetic Counseling and Testing for *VHL*

Simplex Case Is Sufficient for Referral	Presence of > 1 Tumor Is Suggested for Referral
Retinal/CNS HB	Pancreatic cystadenoma
PCC/PGL	PNET
ELST	Epididymal/adnexal cystadenoma*
Clear-cell RCC†	Clear-cell RCC‡

NOTE. See Hampel et al,<sup>56</sup> O'Brien et al,<sup>57</sup> and Shuch et al.<sup>58</sup> Abbreviations: ELST, endolymphatic sac tumor; HB, hemangioblastoma; PCC, pheochromocytoma; PGL, paraganglioma; PNET, pancreatic neuroendocrine tumor; RCC, renal cell carcinoma; *VHL*, von Hippel-Lindau.

\*Bilateral papillary cystadenomas of adnexal/broad ligament are pathognomonic for *VHL*.

†If diagnosed at age < 50 years or one or more close relatives have clear-cell RCC.

‡If diagnosed at age > 50 years or no close relatives have clear-cell RCC.

**Table 2.** *VHL* and Genetics Testing Resources

Organization	Web Site
VHL Family Alliance	<a href="http://www.vhl.org">www.vhl.org</a>
GeneReviews-VHL	<a href="http://www.ncbi.nlm.nih.gov/books/NBK1463/PDQ_Summaries-VHL">www.ncbi.nlm.nih.gov/books/NBK1463/PDQ_Summaries-VHL</a>
PDQ Summaries-VHL	<a href="http://www.cancer.gov/types/kidney/hp/kidney-genetics-pdq">www.cancer.gov/types/kidney/hp/kidney-genetics-pdq</a>
National Society of Genetic Counselors	<a href="http://www.nsgc.org">www.nsgc.org</a>
Genetic Testing Registry	<a href="http://www.ncbi.nlm.nih.gov/gtr/">www.ncbi.nlm.nih.gov/gtr/</a>
GeneTests	<a href="http://www.genetests.org/">www.genetests.org/</a>

Abbreviation: PDQ, physician data query; *VHL*, von Hippel-Lindau.

years,<sup>58</sup> although for clinical purposes, we often cast a wider net and consider referral for diagnoses at an age  $\leq$  50 years, or with the presence of a family history or other syndromic features.<sup>62</sup> More than 40% of PCC and/or PGL are associated with germline mutation in any of 12 genes, which supports multigene panel testing for all cases of PCC and/or PGL.<sup>54</sup>

Many laboratories worldwide now offer multigene panels that target PCC and/or PGL and RCC. It is critical to include genetics professionals in the testing process as they have the skills to ensure that the appropriate testing method is selected on the basis of their astute analysis of personal and family history. If more than one syndrome is in the differential diagnosis, genetics professionals will review the implications of each syndrome so that the patient is providing true informed consent and that there are no surprise diagnoses. In addition, genetics teams have expertise in interpretation of genetic testing results, which is particularly crucial in the realm of next-generation sequencing as results are often not straightforward and misinterpretation can have devastating effects on patient and family. Whereas positive genetic test results seem relatively straightforward, there are many issues to consider once a diagnosis has been made. Genetics professionals can help individuals cope with a diagnosis and develop strategies to share this information with at-risk family members. A negative genetic test result must be interpreted in the context of the personal and family history of the individual—often it does not rule out a clinical or a hereditary cause for the cancer or disease in the family. In this instance, an individualized approach must be adopted for further surveillance recommendations, taking into account personal and family history and patient preferences. Lastly, variants of uncertain significance (VUS) that are identified via genetic testing need to be carefully considered. A VUS means a genetic change is identified but the significance of that change is unknown. The patient and the medical team must understand that these results do not immediately affect medical management recommendations, which are always based on personal and family history, until the VUS is reclassified—a process that could take several months or years.

### CLINICAL AND GENETIC FEATURES

Incidence of *VHL* is approximately one in 36,000,<sup>63</sup> and it has a penetrance of > 90% by age 65 years, with a mean age at tumor diagnosis of 26 years (range, 1 to 70 years).<sup>3,64</sup> The breakdown of

frequency and mean age at diagnosis for specific VHL tumor types is outlined in Table 3. Long-term outcomes in individuals with VHL continue to improve as a result of improvements in surveillance and treatment of RCC and CNS HB, the leading causes of morbidity and mortality in patients with VHL.<sup>64</sup> Phenotypic heterogeneity, both inter- and intrafamilial, is a hallmark of VHL.<sup>65,66</sup> Clinically, VHL is classified into type 1 or type 2 disease on the basis of the frequency of RCC and PCC (Table 4).<sup>70-72</sup> Although this classification facilitates genotype-phenotype studies, reviewed elsewhere,<sup>7</sup> it has limited clinical use as families move between subtypes as additional tumors are discovered.<sup>6,23</sup> In brief, families with truncating mutations or exon deletions infrequently manifest PCC and, thus, usually have type 1 disease characterized by increased incidence of RCC and retinal and CNS HBs but not PCC, whereas type 2 VHL is characterized by missense mutations that predispose to PCC, some with PCC alone (type 2C), and other families with additional manifestations.<sup>4,60-72</sup> Because the relationship between genotype and phenotype is still evolving, it is recommended that all individuals with a diagnosis of VHL follow the same surveillance protocol, which screens for all possible manifestations of the disease.

As with most tumor suppressors, the majority of VHL mutations are private; however, recurrent founder mutations are well documented. The most well-characterized founder mutations are those originating from Germany: c.T292C (previously c.T505; p.Y98H) in families from the Black Forest region and c.T334C (previously c.T547C; p.Y112H) in families from east central Germany (Leipzig).<sup>70,74-78</sup> These families have migrated across Europe and America, especially to Western Pennsylvania. Both mutations predispose to type 2A VHL, with a high risk of PCC, a moderate risk of retinal and CNS HB, and a low risk of RCC.<sup>67,77</sup>

A mutation hot spot is at codon 167 as a result of the presence of CpG dinucleotide, with attendant risks of deamination.<sup>72</sup> There have been > 82 families identified with mutations at this location, which represent approximately 43% of mutations in American and

Canadian families with VHL type 2.<sup>7,60,72</sup> Individuals with mutations at this location have a high risk of developing PCC (approximately 62%) and RCC.<sup>72</sup>

VHL genotype-phenotype correlation is further complicated by a unique congenital polycythemia syndrome that is caused by biallelic—homozygous/compound heterozygous—mutations of the VHL gene without any manifestations of VHL disease.<sup>4</sup> The most frequent mutation in this syndrome is c.C598T (p.R200W).<sup>79</sup> Individuals who are homozygous for this mutation have polycythemia, pulmonary hypertension, varicose veins, elevated serum VEGF concentrations, and occasional vertebral hemangiomas.<sup>4,80</sup>

VHL is inherited in an autosomal-dominant manner, with the majority of cases (80%) inherited from an affected parent and ≤ 20% de novo.<sup>81,82</sup> Once a VHL mutation is identified in a family, it is recommended that genetic testing be offered to the parents of the individual, if they are available, even with a seemingly absent family history, as family history may seem to be negative as a result of reduced penetrance or later age of onset, variable expressivity among family members, or death of an affected parent before the onset of symptoms.<sup>83</sup> Mosaicism occurs when a new mutation arises in some but not all tissues, which can result in negative genetic testing if an unaffected cell or tissue type is sampled.<sup>82</sup> There are data that suggest that mosaicism is an under-recognized phenomenon in VHL, which could result in an overestimation of true cases of de novo mutations in probands. Generally, patients with mosaicism tend to be more mildly affected or asymptomatic,<sup>83</sup> although this is not always the case, and mosaicism has been confirmed in individuals with classic VHL disease as well.<sup>84,85</sup> It is now recommended that additional testing methods be used to rule out mosaicism in the parents of a patient with proband with a seemingly de novo mutation and in cases moderately or highly suspicious of VHL in whom standard testing methods have failed to detect a disease-causing mutation.<sup>82-85</sup> Various techniques have been successful in identifying mosaic mutations,<sup>82,84</sup> and as an alternative, different tissue types can be sampled, including skin fibroblasts and oral epithelial cells.<sup>83,86</sup> Detection of mosaicism is critical in terms of confirming a diagnosis and estimating the risk to siblings and offspring.<sup>84,85</sup> As next-generation sequencing replaces Sanger sequencing, mosaic cases may be more easily detected, which could provide the data needed to elucidate the true frequency of mosaicism in VHL.

## GENETIC COUNSELING AND SURVEILLANCE CONSIDERATIONS

Genotype-phenotype issues are only of scientific value at this point and play no role in clinical or counseling care for patients with VHL. Given the complexity of disease, a multidisciplinary approach with coordination of care among multiple medical specialists, including genetics professionals, is essential for individuals with VHL. Although preventative treatment cannot yet be offered for VHL, it is generally accepted that comprehensive surveillance programs improve outcomes by preventing avoidable morbidity and mortality.<sup>4,87,88</sup> Therefore, genetics professionals may take a more directive approach to their counseling because of the importance of initiating or continuing screening for gene carriers and discontinuing it for noncarriers.<sup>88</sup> At-risk family members who received genetic counseling were more likely to

**Table 3.** Frequency and Age of Onset of VHL-Associated Tumors

Tumor	Mean (range) Age of Onset, Years	Frequency in Patients, %
CNS		
Retinal HB	25 (1-68)	25-60
ELST	22 (12-50)	10-15
Craniospinal HB overall	30 (9-70)	60-80
Cerebellum	33 (9-78)	44-72
Brainstem	32 (12-46)	10-25
Spinal cord	33 (11-66)	13-50
Visceral		
RCC or cysts	39 (13-70)	25-75
PCC	27 (5-58)	10-25
PNET or cyst	36 (5-70)	35-75*
Epididymal cystadenoma	Unknown	25-60
Broad ligament cystadenoma	Unknown (16-46)	Unknown

NOTE. Adapted from Lonser et al<sup>3</sup> and Maher and Kaelin.<sup>59</sup> See also Maher et al<sup>4</sup> and Richard et al.<sup>46</sup>

Abbreviations: ELST, endolymphatic sac tumor; HB, hemangioblastoma; PCC, pheochromocytoma; PNET, pancreatic neuroendocrine tumor; RCC, renal cell carcinoma.

\*Frequency of PNET is 11% to 17%, whereas that of pancreatic cysts is ≤ 75%.<sup>46</sup>



Table 4. VHL Subtypes

VHL Subtype	VHL Mutation Type	High Risk	Low Risk
Type 1	Deletions, insertions, truncations, missense	CNS/retinal HB, RCC	PCC
Type 1B	Contiguous gene deletions encompassing <i>VHL</i>	CNS/retinal HB	PCC, RCC (risk may increase if <i>C3</i> or <i>f10</i> remains increased)
Type 2A	Missense (eg, p.Y98H, p.Y112H, p.V116F)	CNS/retinal HB, PCC	RCC
Type 2B	Missense (eg, p.R167Q, p.R167W)	CNS/retinal HB, RCC, PCC	
Type 2C	Missense (eg, p.V84L p.L188V)	PCC	CNS/retinal HB, RCC absent

NOTE. See Chen et al,<sup>67</sup> Maher et al,<sup>68</sup> and Hes et al.<sup>69</sup>  
Abbreviations: HB, hemangioblastoma; PCC, pheochromocytoma; RCC, renal cell carcinoma; VHL, von Hippel-Lindau.

pursue *VHL* testing compared with those who were only informed of the possibility of testing through a relative or written material.<sup>89</sup> Genetics professionals can aid families in the risk communication process and help identify and work through barriers to genetic testing and follow-up.

### Presymptomatic Testing of Children

Because children of patients with VHL have a 50% chance of being affected, the topic of genetic testing for VHL in children is one that arises often in clinical care. For healthy children, many professional statements and guidelines support the recommendation that genetic testing be pursued only if the condition is associated with childhood onset and if a positive result leads to effective and safe screening and/or interventional options, thereby reducing morbidity and mortality.<sup>90,91</sup> Although the average age of onset of VHL tumors is in the third decade of life, some patients develop tumors at age younger than 10 years and as early as infancy; therefore, presymptomatic genetic testing for VHL is justified,<sup>92</sup> and also may identify those children who did not inherit the familial *VHL* mutation, thus sparing them from a lifetime of clinical screening.

Many factors should be considered before presymptomatic genetic testing is pursued. Genetic testing may be offered to a family with a child who is too young to give their informed assent, which can lead to a potential loss of autonomy for that child who may grow up with genetic information that they were not able to elect to know themselves.<sup>93</sup> Testing can also be associated with many complex emotions, including anxiety, denial, and guilt on the part of the parent who is affected with VHL.<sup>89,91</sup> Many families may have lived through the experience of loved ones who developed tumors or other VHL-related complications at young ages that may impact coping when children are found to carry the VHL mutation.<sup>89,93</sup> In addition, at-risk or affected children may be treated differently than their noncarrier siblings.<sup>89,93-95</sup> Surveillance fatigue and/or burnout should also be considered in families who are considering testing their children for VHL as the surveillance is initiated in childhood for mutation-positive children and is lifelong.<sup>96</sup> This topic is discussed more extensively in subsequent section, Psychosocial Impact of VHL, Including the Burden of Lifelong Surveillance. It is strongly recommended that genetic counseling for presymptomatic genetic testing be conducted by a genetics professional in a comfortable environment and with the option of having multiple genetic counseling sessions as necessary.<sup>89,91,93,97</sup>

### Genetic Communication Needs of Children With VHL

A major question that arises from parents and health professionals is how and when to inform children of their genetic status. Research specific to communication among families with VHL is limited, but studies on the communication needs of children with other genetic conditions have found that the majority of patients would have preferred receiving information before age 12 years and ideally between the ages of 6 and 10 years. The majority parents with VHL want their children tested either at birth or at least before the age of 10 years.<sup>98,99</sup> Adolescents preferred that the focus of a genetic counseling session be on understanding and managing their health condition rather than on their reproductive risks. They also identified their parents as their primary source of genetic information—with doctors or other health professionals coming second to this—and many wanted to be seen by their health care provider with their parents present.<sup>100</sup>

Parents are often unsure of the best way to discuss information regarding a genetic diagnosis with their children, and common concerns include how the information may impact the self-esteem, coping, and anxiety level of their child.<sup>101</sup> Parents may feel overwhelmed by the information, not knowing how, when, or what information to provide.<sup>95</sup> In addition, they may feel insecure in their own understanding of that information.<sup>100</sup> Studies show that parents feel that guidance and support from health care professionals on how to deliver this information is important, although often not available.<sup>95</sup> An important part of the genetic counseling process is to discuss with families how they plan to present the information to their children throughout different stages of their lives.<sup>102</sup>

Children report their preference of learning about their genetic condition gradually through open and continuous communication during childhood.<sup>94</sup> In this way, children are provided with developmentally appropriate information of which they can ask questions and understand at their own pace, which helps them come to terms with their genetic risk in a natural and self-driven way.<sup>95,102</sup> This genetic information then becomes part of the family narrative or culture; talking about those in the family who are also affected helps normalize the information by making it part of a shared family identity.<sup>94,95,102</sup>

In contrast, not acknowledging the genetic condition in the family dissuades children from asking questions, as they do not want to upset their parents.<sup>94,95,101,102</sup> Genetics professionals can help facilitate the communication process, elicit any perceived barriers to communication, and provide a safe place for

parents to practice these discussions. Resources that provide parents with techniques, diagrams, and appropriate language to use when communicating with their children can be developed, and support groups or additional professional psychosocial support should be encouraged.<sup>95,102</sup> One such example available to the VHL community is the VHL Alliance Handbook Kids' Edition.<sup>103</sup>

### Preconception Counseling, Including Pregnancy-Related Risks

Availability of genetic testing for VHL introduces options for couples who are at risk of having a child with VHL, including prenatal diagnosis and preimplantation genetic diagnosis (PGD). Although perceptions may vary across countries, the French VHL study group interviewed 18 women and 13 men with VHL and found that a significant proportion of them (11 women and 11 men; approximately 70%) intended to use prenatal diagnosis in the case of a pregnancy, although one half of the group would not terminate an affected pregnancy or were undecided because they hoped for better outcomes and treatments in the future for their children compared with their own experience of VHL.<sup>98</sup> PGD uses in vitro fertilization techniques to identify genetic mutations within embryos before implantation.<sup>104</sup> This is a technology that patients with VHL are interested in exploring: 71% of Australian patients (10 of 14 respondents) viewed it as a favorable option to avoid having a child with VHL compared with 33% (26 of 79 respondents) in the Dutch population.<sup>89,105</sup> At least 11 children have already been born using this method from the French VHL study group, which now comprises 802 individuals living with VHL, 28 of whom have attempted to have children using PGD (unpublished data). It is important that patients understand the practical limitations of PGD, namely, the cost, as many insurance companies currently will not cover the service. In addition, there are limitations to the technology that must be communicated, including the germline mutation in the family must be known; there are no data about the effect of in vitro fertilization–related hormone treatment of egg harvest on tumor development; and the process often takes > 1 year, and if a tumor develops in that period, application of PGD may be delayed or abandoned.

Another factor that complicates reproductive decision making in patients with VHL is the pregnancy-related risk that is associated with the disease. Whereas pregnancy is not typically considered a contraindication in patients with VHL, certain precautions must be considered. Available studies on the subject show conflicting results regarding development or progression of tumors and disease-related complications.<sup>106-108</sup> It is critical to evaluate for potentially life-threatening complications, namely, PCC or hydrocephalus as a result of cerebellar HB, before attempting to become pregnant.<sup>106</sup> Many groups also advocate for additional screening and monitoring during pregnancy, including routine evaluation of retinal angiomas, noncontrast magnetic resonance imaging during the fourth month for CNS lesions, plasma metanephrine testing during early, mid, and late pregnancy, and consideration of delivery via caesarian section to lower the chance of increased intracranial pressure.<sup>106,109</sup> As long as patients are closely observed by a multidisciplinary team, pregnancy is typically a safe option for

women with VHL but other options, such as surrogacy and adoption, can also be explored.

### Psychosocial Impact of VHL, Including the Burden of Lifelong Surveillance

There are few data on the psychosocial impact of complex tumor predisposition syndromes with limited prevention options; however, the data that do exist suggest that a significant proportion of those affected by VHL and those who care for them experience clinically important levels of distress.<sup>110</sup> Those who experience the death of a close relative as a result of VHL during adolescence are particularly vulnerable. Approximately one third of participants had received professional psychosocial support, and the rest seemed amenable to it.<sup>110</sup> Many patients struggle with the complex medical, social, and psychologic aspects of VHL, for example, uncertainty about future tumor development, frustration regarding lifelong screening, strained relationships with family and partners, difficulty communicating with others about VHL, and complex decisions regarding childbearing.<sup>89,111</sup>

A highly sensitive concern for patients with VHL is the burden of lifelong surveillance. Suggested surveillance guidelines are summarized in Table 5. Whereas surveillance can pick up early-stage lesions that are amenable to treatment, that is, retinal angiomas, it also identifies lesions for which there is no immediate clinical benefit, that is, pancreatic cysts, and even findings unrelated to VHL that require further follow-up.<sup>88</sup> For these reasons, most individuals with VHL view surveillance regimens as a necessary yet anxiety-provoking burden that incite a variety of responses, including denial, anger, fear, sadness, and anxiety.<sup>89</sup>

**Table 5.** Suggested VHL Surveillance Guidelines

Age, Years	Screening	Frequency
0-4	Eye/retinal exam with indirect ophthalmoscope	Annually
	Physical exam with blood pressure check and neurologic assessment	Annually
5-15	All the above, plus: Test for plasma-free metanephrines or urinary metanephrines using 24-hour urine test	Annually
	Abdominal ultrasound from age ≤ 8 years if indicated; abdominal MRI or functional imaging scan only if biochemical abnormalities found	Annually
	Audiology assessment; in the case of repeated ear infections, MRI with contrast of the internal auditory canal	2-3 years (1 year if tinnitus, hearing loss, or vertigo)
≥ 16	All the above, plus: Quality ultrasound of abdomen MRI of abdomen with and without contrast MRI of brain and cervical spine	Annually Every 2 years Every 1-2 years

NOTE. See VHL Family Alliance,<sup>109</sup> Binderup et al,<sup>112</sup> and Poulsen et al.<sup>113</sup> Abbreviations: MRI, magnetic resonance imaging; VHL, von Hippel-Lindau.

Although the uptake of genetic testing is generally high in families with VHL, as many as 60% of identified mutation carriers will be lost to follow-up 5 years after testing, which suggests that patient concerns regarding surveillance are not being appropriately addressed.<sup>92</sup> As current VHL surveillance guidelines are largely based on expert medical opinion and limited evidence, health care providers also struggle with determining optimal surveillance recommendations while also minimizing patient psychologic distress (“scanxiety”) and expenses to the health care system.<sup>112</sup>

Recently, nationwide efforts by VHL care teams in Denmark and the Netherlands have sought to address these issues by providing additional evidence regarding the optimal initiation and frequency of surveillance regimes.<sup>112-116</sup> Kruizinga et al<sup>115</sup> calculated the organ-specific age at which to initiate surveillance as well as surveillance intervals. These were age 0 years/at birth for the adrenal glands and a 4-year interval between screenings, age 7 years for the retina with a 2-year interval, age 14 years for the cerebellum with a 1-year interval, age 15 years for the spinal cord with a 1-year interval, age 16 years for the pancreas with a 2-year interval, and age 18 years for the kidneys with a 1-year interval. These findings represent significant deviation from current surveillance guidelines, in particular, in terms of adrenal and retinal surveillance, with a later initiation of retinal surveillance (by 6 years), with a 1-year longer interval follow-up, and an earlier initiation of adrenal surveillance (by 5 years) with a 3-year longer interval follow-up.<sup>115</sup> They were also able to calculate the age at which the probability of developing a first manifestation of VHL is < 5% (age 34 years), which represents a reasonable age at which to stop surveillance, for instance, in at-risk family members of a proband whose disease-causing mutation cannot be identified.<sup>115</sup>

Other groups have suggested possible modifications in the current guidelines for other organs. For example, Poulson et al<sup>113</sup> found that biennial CNS examinations led to a relatively high rate (7.2%) of interval lesions with clinical consequences, whereas annual screening reduced the risk to an acceptable rate of 2.7%. Binderup et al<sup>112</sup> pointed out that these and other studies have assumed the risk of new tumor development is constant throughout the lifetime of a patient with VHL; however, risk can vary significantly with age and genotype and depends on the organ involved. They found that tumor development was highest at age 30 to 34 years, and when broken down by the most common organs affected in their cohort, the risk of retinal tumors was highest during teenage years (age 15 to 19 years) and the risk of cerebellar tumors was highest during age 30 to 39 years. Therefore, adherence to surveillance of these organs during those ages should be particularly encouraged. In addition, Binderup et al<sup>112</sup> stratified by genotype and found that carriers of truncating mutations had significantly higher rates of manifestations compared with missense mutation carriers, with the exception of retinal tumors, which were significantly less frequent in carriers of truncating mutations. Whereas some argue that surveillance recommendations should not be influenced by specific mutations, as the second hit that results in tumor development is random, the goal in any hereditary cancer predisposition syndrome is to be able to tailor management guidelines on the basis of individual factors, such as genotype, environmental stimuli, or other genetic alterations.

As all of the previously mentioned studies represent significant deviations from current surveillance guidelines, the results need to be confirmed by larger prospective studies in other geographic populations before incorporation into clinical practice.

In terms of practical strategies for increasing adherence to surveillance protocols, it is crucial for health care providers to set expectations before screening with regard to benefits, limitations, and logistical matters, including how and when results will be relayed. It is important to engage the whole family in this discussion, if possible, as studies have shown that family members tend to take the same stance toward long-term surveillance.<sup>92</sup> Families must also understand that the absence of symptoms is not a reason to delay screening; the variable nature of disease within families can create the misconception that only members who are most symptomatic require close observation.<sup>92,116</sup> It is important that health care providers adhere to national guidelines for surveillance because patients who are given variable advice at different institutions tend not to fully adhere to the advice.<sup>116</sup> If feasible, a case manager—a specially trained nurse practitioner or genetic counselor—for families with VHL is advised to serve as a primary contact and to help coordinate multidisciplinary care, including medical follow-up and psychosocial needs.<sup>116</sup>

The role of patient associations is crucial in disseminating up-to-date information about rare diseases to patients and physicians. The VHL Alliance, established in 1994, has a worldwide presence, actively contributes to supporting VHL research, and works with experts in the field to establish current surveillance recommendations. There are now National VHL networks and/or specialized clinical care centers in > 30 countries that offer specialized medical and psychosocial support as well as the opportunity to connect with patients with VHL from around the world.<sup>46,109</sup> Table 4 provides a list of VHL and genetics resources for patients, caregivers, and managing physicians.

In summary, VHL is a complex and intriguing disease from a genetic, clinical, and psychosocial standpoint. It is a disease that spans a breadth of pediatric and adult oncologic subspecialties, and, as such, providers should be aware of when to consider a diagnosis and the special considerations involved in genetic work-up and familial testing. There have been many advances in the understanding of VHL over the years, and continued discoveries will lend insight into the treatment of a variety of hereditary and sporadic cancers as well as to help optimize all aspects of care for patients with VHL and their families. Strategies may need to adjust as new therapies are expected to become available, likely on an organ-by-organ basis. For example, in the treatment of ccRCC, both patients with VHL and sporadic patients have enormously benefited from VHL-driven molecular biology, in particular, VEGF pathway inhibitors such as sunitinib and pazopanib, which currently form the only two first-line therapies recommended for treatment of metastasized RCC. However, recent US Food and Drug Administration approval of immuno-oncological agents, such as nivolumab, for second-line treatment of advanced RCC<sup>117</sup> should be carefully followed in patients with VHL, as presumably a single patient with VHL may have hundreds or more subclinical lesions throughout his or her body. Exciting developments in gene therapy offer promise for patients with

VHL,<sup>118</sup> but, for now, surveillance remains the best approach for disease management.

#### AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at [www.jco.org](http://www.jco.org).

#### REFERENCES

1. Maher ER, Yates JR, Harries R, et al: Clinical features and natural history of von Hippel-Lindau disease. *Q J Med* 77:1151-1163, 1990
2. Friedrich CA: Von Hippel-Lindau syndrome. A pleomorphic condition. *Cancer* 86:2478-2482, 1999 (suppl 1)
3. Lonsler RR, Glenn GM, Walther M, et al: von Hippel-Lindau disease. *Lancet* 361:2059-2067, 2003
4. Maher ER, Neumann HP, Richard S: von Hippel-Lindau disease: A clinical and scientific review. *Eur J Hum Genet* 19:617-623, 2011
5. Lindau A: Studies on cerebellar cysts: Construction, pathogenesis and relationships to retinal angiomas. [in German]. *Acta Pathol et Microbiol Scand* 1:1-128, 1926 (suppl 1)
6. Latif F, Tory K, Gnarr J, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. *Science* 260:1317-1320, 1993
7. Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, et al: Genetic analysis of von Hippel-Lindau disease. *Hum Mutat* 31:521-537, 2010
8. Bérout C, Joly D, Gallou C, et al: Software and database for the analysis of mutations in the VHL gene. *Nucleic Acids Res* 26:256-258, 1998
9. Melmon KL, Rosen SW: Lindau's disease. Review of the literature and study of a large kindred. *Am J Med* 36:595-617, 1964
10. Neumann HP: Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome. *Vasa* 16:220-226, 1987
11. Choyke PL, Glenn GM, Walther MM, et al: von Hippel-Lindau disease: Genetic, clinical, and imaging features. *Radiology* 194:629-642, 1995
12. Prowse AH, Webster AR, Richards FM, et al: Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. *Am J Hum Genet* 60:765-771, 1997
13. Crossey PA, Foster K, Richards FM, et al: Molecular genetic investigations of the mechanism of tumorigenesis in von Hippel-Lindau disease: Analysis of allele loss in VHL tumours. *Hum Genet* 93:53-58, 1994
14. Tory K, Brauch H, Linehan M, et al: Specific genetic change in tumors associated with von Hippel-Lindau disease. *J Natl Cancer Inst* 81:1097-1101, 1989
15. Zbar B, Brauch H, Talmadge C, et al: Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. *Nature* 327:721-724, 1987
16. Kaelin WG Jr: The von Hippel-Lindau tumor suppressor gene and kidney cancer. *Clin Cancer Res* 10:6290S-6295S, 2004
17. Gerlinger M, Horswell S, Larkin J, et al: Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. *Nat Genet* 46:225-233, 2014
18. Gläsker S, Bender BU, Apel TW, et al: Reconsideration of biallelic inactivation of the VHL

tumour suppressor gene in hemangioblastomas of the central nervous system. *J Neurol Neurosurg Psychiatry* 70:644-648, 2001

19. Oberstrass J, Reifenberger G, Reifenberger J, et al: Mutation of the Von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system. *J Pathol* 179:151-156, 1996
20. Eng C, Crossey PA, Mulligan LM, et al: Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic pheochromocytomas. *J Med Genet* 32:934-937, 1995
21. Gossage L, Eisen T, Maher ER: VHL, the story of a tumour suppressor gene. *Nat Rev Cancer* 15:55-64, 2015
22. Pagon RA, Adam MP, Ardinger HH, et al (eds): Von Hippel-Lindau syndrome, in: *GeneReviews*. Seattle, WA, University of Washington, 1993
23. Stebbins CE, Kaelin WG Jr, Pavletich NP: Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function. *Science* 284:455-461, 1999
24. McClellan AJ, Scott MD, Frydman J: Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways. *Cell* 121:739-748, 2005
25. Lee S, Nakamura E, Yang H, et al: Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer. *Cancer Cell* 8:155-167, 2005
26. Hergovich A, Lisztwan J, Thoma CR, et al: Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. *Mol Cell Biol* 26:5784-5796, 2006
27. Lolkema MP, Mehra N, Jorna AS, et al: The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery. *Exp Cell Res* 301:139-146, 2004
28. Schermer B, Ghenoiu C, Bartram M, et al: The von Hippel-Lindau tumor suppressor protein controls cilogenesis by orienting microtubule growth. *J Cell Biol* 175:547-554, 2006
29. Dere R, Perkins AL, Bawa-Khalife T, et al:  $\beta$ -Catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma. *J Am Soc Nephrol* 26:553-564, 2015
30. Ding XF, Zhou J, Hu QY, et al: The tumor suppressor pVHL down-regulates never-in-mitosis A-related kinase 8 via hypoxia-inducible factors to maintain cilia in human renal cancer cells. *J Biol Chem* 290:1389-1394, 2015
31. Troilo A, Alexander I, Muehl S, et al: HIF1 $\alpha$  deubiquitination by USP8 is essential for cilogenesis in normoxia. *EMBO Rep* 15:77-85, 2014
32. Hell MP, Duda M, Weber TC, et al: Tumor suppressor VHL functions in the control of mitotic fidelity. *Cancer Res* 74:2422-2431, 2014
33. Yang H, Minamishima YA, Yan Q, et al: pVHL acts as an adaptor to promote the inhibitory phosphorylation

of the NF-kappaB agonist Card9 by CK2. *Mol Cell* 28:15-27, 2007

34. Kuznetsova AV, Meller J, Schnell PO, et al: von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. *Proc Natl Acad Sci USA* 100:2706-2711, 2003
35. Yi Y, Mikhaylova O, Mamedova A, et al: von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas. *Clin Cancer Res* 16:5142-5152, 2010
36. Roe JS, Kim HR, Hwang IY, et al: Phosphorylation of von Hippel-Lindau protein by checkpoint kinase 2 regulates p53 transactivation. *Cell Cycle* 10:3920-3928, 2011
37. Young AP, Schlisio S, Minamishima YA, et al: VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. *Nat Cell Biol* 10:361-369, 2008
38. Okuda H, Saitoh K, Hirai S, et al: The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. *J Biol Chem* 276:43611-43617, 2001
39. Kurban G, Hudon V, Duplan E, et al: Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. *Cancer Res* 66:1313-1319, 2006
40. Kurban G, Duplan E, Ramlal N, et al: Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2. *Oncogene* 27:1004-1012, 2008
41. Stickle NH, Chung J, Klco JM, et al: pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. *Mol Cell Biol* 24:3251-3261, 2004
42. Bishop T, Lau KW, Epstein AC, et al: Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in *Caenorhabditis elegans*. *PLoS Biol* 2:e289, 2004
43. Koochekpour S, Jeffers M, Wang PH, et al: The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. *Mol Cell Biol* 19:5902-5912, 1999
44. Tang N, Mack F, Haase VH, et al: pVHL function is essential for endothelial extracellular matrix deposition. *Mol Cell Biol* 26:2519-2530, 2006
45. Fisher R, Horswell S, Rowan A, et al: Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. *Genome Biol* 15:433, 2014
46. Richard S, Gardie B, Couvé S, et al: Von Hippel-Lindau: How a rare disease illuminates cancer biology. *Semin Cancer Biol* 23:26-37, 2013
47. Hes FJ, van der Luijt RB, Janssen AL, et al: Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease

#### AUTHOR CONTRIBUTIONS

**Conception and design:** All authors

**Collection and assembly of data:** Sarah M. Nielsen, Lindsay Rhodes

**Data analysis and interpretation:** Sarah M. Nielsen, Lindsay Rhodes

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors



identified by DNA sequencing, southern blot analysis and multiplex ligation-dependent probe amplification. *Clin Genet* 72:122-129, 2007

48. Hes FJ, McKee S, Taphoorn MJ, et al: Cryptic von Hippel-Lindau disease: Germline mutations in patients with haemangioblastoma only. *J Med Genet* 37:939-943, 2000
49. Reference deleted
50. Richard S, David P, Marsot-Dupuch K, et al: Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease. *Neurosurg Rev* 23:1-22, discussion 23-24, 2000
51. Woodward ER, Wall K, Forsyth J, et al: VHL mutation analysis in patients with isolated central nervous system haemangioblastoma. *Brain* 130:836-842, 2007
52. Singh A, Shields J, Shields C: Solitary retinal capillary hemangioma: Hereditary (von Hippel-Lindau disease) or nonhereditary? *Arch Ophthalmol* 119:232-234, 2001
53. Brauch H, Hoepfner W, Jähmig H, et al: Sporadic pheochromocytomas are rarely associated with germline mutations in the *vh*/tumor suppressor gene or the ret protooncogene. *J Clin Endocrinol Metab* 82:4101-4104, 1997
54. Fishbein L, Merrill S, Fraker DL, et al: Inherited mutations in pheochromocytoma and paraganglioma: Why all patients should be offered genetic testing. *Ann Surg Oncol* 20:1444-1450, 2013
55. Neumann HP, Bender BU, Berger DP, et al: Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. *J Urol* 160:1248-1254, 1998
56. Hampel H, Bennett RL, Buchanan A, et al: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: Referral indications for cancer predisposition assessment. *Genet Med* 17:70-87, 2015
57. O'Brien FJ, Danapal M, Jairam S, et al: Manifestations of Von Hippel Lindau syndrome: A retrospective national review. *QJM* 107:291-296, 2014
58. Shuch B, Vourganti S, Ricketts CJ, et al: Defining early-onset kidney cancer: Implications for germline and somatic mutation testing and clinical management. *J Clin Oncol* 32:431-437, 2014
59. Maher ER, Kaelin WG Jr: von Hippel-Lindau disease. *Medicine (Baltimore)* 76:381-391, 1997
60. Stolle C, Glenn G, Zbar B, et al: Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. *Hum Mutat* 12:417-423, 1998
61. Cho HJ, Ki CS, Kim JW: Improved detection of germline mutations in Korean VHL patients by multiple ligation-dependent probe amplification analysis. *J Korean Med Sci* 24:77-83, 2009
62. Reaume MN, Graham GE, Tomiak E, et al: Canadian guideline on genetic screening for hereditary renal cell cancers. *Can Urol Assoc J* 7:319-323, 2013
63. Maher ER, Iselius L, Yates JR, et al: Von Hippel-Lindau disease: A genetic study. *J Med Genet* 28:443-447, 1991
64. Wilding A, Ingham SL, Lalloo F, et al: Life expectancy in hereditary cancer predisposing diseases: An observational study. *J Med Genet* 49:264-269, 2012
65. Glenn GM, Daniel LN, Choyke P, et al: Von Hippel-Lindau (VHL) disease: Distinct phenotypes suggest more than one mutant allele at the VHL locus. *Hum Genet* 87:207-210, 1991
66. Neumann HP, Wiestler OD: Clustering of features of von Hippel-Lindau syndrome: Evidence for a complex genetic locus. *Lancet* 337:1052-1054, 1991
67. Chen F, Slife L, Kishida T, et al: Genotype-phenotype correlation in von Hippel-Lindau disease: Identification of a mutation associated with VHL type 2A. *J Med Genet* 33:716-717, 1996
68. Maher ER, Webster AR, Richards FM, et al: Phenotypic expression in von Hippel-Lindau disease: Correlations with germline VHL gene mutations. *J Med Genet* 33:328-332, 1996
69. Hes F, Zewald R, Peeters T, et al: Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene. *Hum Genet* 106:425-431, 2000
70. Chen F, Kishida T, Yao M, et al: Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. *Hum Mutat* 5:66-75, 1995
71. Zbar B, Kishida T, Chen F, et al: Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. *Hum Mutat* 8:348-357, 1996
72. Crossey PA, Richards FM, Foster K, et al: Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. *Hum Mol Genet* 3:1303-1308, 1994
73. Reference deleted
74. Mulvihill JJ, Ferrell RE, Carty SE, et al: Familial pheochromocytoma due to mutant von Hippel-Lindau disease gene. *Arch Intern Med* 157:1390-1391, 1997
75. Tisherman SE, Gregg FJ, Danowski TS: Familial pheochromocytoma. *JAMA* 182:152-156, 1962
76. Tisherman SE, Tisherman BG, Tisherman SA, et al: Three-decade investigation of familial pheochromocytoma. An allele of von Hippel-Lindau disease? *Arch Intern Med* 153:2550-2556, 1993
77. Brauch H, Kishida T, Glavac D, et al: Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: Evidence for a founder effect. *Hum Genet* 95:551-556, 1995
78. Crossey PA, Eng C, Ginalska-Malinowska M, et al: Molecular genetic diagnosis of von Hippel-Lindau disease in familial pheochromocytoma. *J Med Genet* 32:885-886, 1995
79. Ang SO, Chen H, Gordeuk VR, et al: Endemic polycythemia in Russia: Mutation in the VHL gene. *Blood Cells Mol Dis* 28:57-62, 2002
80. Gordeuk VR, Sergueeva AI, Miasnikova GY, et al: Congenital disorder of oxygen sensing: Association of the homozygous Chuvasch polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. *Blood* 103:3924-3932, 2004
81. Glenn G, Choyke P, Zbar B, et al: von Hippel-Lindau disease: clinical review and molecular genetics. *Probl Urol* 4:312-330, 1990
82. Sgambati MT, Stolle C, Choyke PL, et al: Mosaicism in von Hippel-Lindau disease: Lessons from kindreds with germline mutations identified in offspring with mosaic parents. *Am J Hum Genet* 66:84-91, 2000
83. Santarpia L, Sarlis NJ, Santarpia M, et al: Mosaicism in von Hippel-Lindau disease: An event important to recognize. *J Cell Mol Med* 11:1408-1415, 2007
84. Coppin L, Grutzmacher C, Crépin M, et al: VHL mosaicism can be detected by clinical next-generation sequencing and is not restricted to patients with a mild phenotype. *Eur J Hum Genet* 22:1149-1152, 2014
85. Wu P, Zhang N, Wang X, et al: Mosaicism in von Hippel-Lindau disease with severe renal manifestations. *Clin Genet* 84:581-584, 2013
86. Ajzenberg H, Slaats GG, Stokman MF, et al: Non-invasive sources of cells with primary cilia from pediatric and adult patients. *Cilia* 4:8, 2015
87. Priesemann M, Davies KM, Perry LA, et al: Benefits of screening in von Hippel-Lindau disease—Comparison of morbidity associated with initial tumours in affected parents and children. *Horm Res* 66:1-5, 2006
88. Evans DG, Maher ER, Macleod R, et al: Uptake of genetic testing for cancer predisposition. *J Med Genet* 34:746-748, 1997
89. Kasparian NA, Rutstein A, Sansom-Daly UM, et al: Through the looking glass: An exploratory study of the lived experiences and unmet needs of families affected by Von Hippel-Lindau disease. *Eur J Hum Genet* 23:34-40, 2015
90. Ross LF, Saal HM, David KL, et al: Technical report: Ethical and policy issues in genetic testing and screening of children. *Genet Med* 15:234-245, 2013 [Erratum: *Genet Med* 15:321, 2013]
91. Schiffman JD, Geller JI, Mundt E, et al: Update on pediatric cancer predisposition syndromes. *Pediatr Blood Cancer* 60:1247-1252, 2013
92. Rasmussen A, Alonso E, Ochoa A, et al: Uptake of genetic testing and long-term tumor surveillance in von Hippel-Lindau disease. *BMC Med Genet* 11:4, 2010
93. Tischkowitz M, Rosser E: Inherited cancer in children: Practical/ethical problems and challenges. *Eur J Cancer* 40:2459-2470, 2004
94. Metcalfe A, Plumridge G, Coad J, et al: Parents' and children's communication about genetic risk: A qualitative study, learning from families' experiences. *Eur J Hum Genet* 19:640-646, 2011
95. Rowland E, Metcalfe A: Communicating inherited genetic risk between parent and child: A meta-thematic synthesis. *Int J Nurs Stud* 50:870-880, 2013
96. Wolfe Schneider K, Jaspersen K: Unique genetic counseling considerations in the pediatric oncology setting. *Curr Genet Med Rep* 3:65-73, 2015
97. Knapke S, Zelley K, Nichols KE, et al: Identification, management, and evaluation of children with cancer-predisposition syndromes. *Am Soc Clin Oncol Educ Book* 2012:576-584, 2012
98. Levy M, Richard S: Attitudes of von Hippel-Lindau disease patients towards presymptomatic genetic diagnosis in children and prenatal diagnosis. *J Med Genet* 37:476-478, 2000
99. Lips CJ: Clinical management of the multiple endocrine neoplasia syndromes: Results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease. *J Intern Med* 243:589-594, 1998
100. Szybowska M, Hewson S, Antle BJ, et al: Assessing the informational needs of adolescents with a genetic condition: What do they want to know? *J Genet Couns* 16:201-210, 2007
101. Metcalfe A, Coad J, Plumridge GM, et al: Family communication between children and their parents about inherited genetic conditions: A meta-synthesis of the research. *Eur J Hum Genet* 16:1193-1200, 2008
102. McConkie-Rosell A, Heise EM, Spiridigliozzi GA: Genetic risk communication: Experiences of adolescent girls and young women from families with fragile X syndrome. *J Genet Couns* 18:313-325, 2009

103. Alliance VHL: VHLA handbook: Kids' edition.

<http://vhl.org/product/vhl-handbook-kids-edition/>

104. Rechitsky S, Verlinsky O, Chistokhina A, et al: Preimplantation genetic diagnosis for cancer predisposition. *Reprod Biomed Online* 5:148-155, 2002

105. Lammens C, Bleiker E, Aaronson N, et al: Attitude towards pre-implantation genetic diagnosis for hereditary cancer. *Fam Cancer* 8:457-464, 2009

106. Frantzen C, Kruizinga RC, van Asselt SJ, et al: Pregnancy-related hemangioblastoma progression and complications in von Hippel-Lindau disease. *Neurology* 79:793-796, 2012

107. Frantzen C, van Asselt SJ, Kruizinga RC, et al: Letter to the editor: Pregnancy and von Hippel-Lindau disease. *J Neurosurg*. 118:1380, 2013

108. Ye DY, Bakhtian KD, Asthagiri AR, et al: Effect of pregnancy on hemangioblastoma development and progression in von Hippel-Lindau disease. *J Neurosurg* 117:818-824, 2012

109. VHL Family Alliance: The VHL Handbook: What You Need to Know About VHL: A Reference Handbook For People With von Hippel-Lindau Disease, Their Families, and Support Personnel. Boston, MA, VHL Family Alliance, 2014

110. Lammens CR, Bleiker EM, Verhoef S, et al: Psychosocial impact of Von Hippel-Lindau disease: Levels and sources of distress. *Clin Genet* 77: 483-491, 2010

111. Lammens CR, Bleiker EM, Verhoef S, et al: Distress in partners of individuals diagnosed with or at high risk of developing tumors due to rare hereditary cancer syndromes. *Psychooncology* 20:631-638, 2011

112. Binderup ML, Budtz-Jørgensen E, Bisgaard ML: Risk of new tumors in von Hippel-Lindau patients depends on age and genotype. *Genet Med* 18:89-97, 2016

113. Poulsen ML, Budtz-Jørgensen E, Bisgaard ML: Surveillance in von Hippel-Lindau disease (vHL). *Clin Genet* 77:49-59, 2010

114. Binderup ML, Bisgaard ML, Harbud V, et al: Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition. *Dan Med J* 60:B4763, 2013


115. Kruizinga RC, Sluiter WJ, de Vries EG, et al: Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations. *Endocr Relat Cancer* 21:63-71, 2013

116. Lammens CR, Aaronson NK, Hes FJ, et al: Compliance with periodic surveillance for Von-Hippel-Lindau disease. *Genet Med* 13:519-527, 2011

117. Motzer RJ, Escudier B, McDermott DF, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med* 373:1803-1813, 2015

118. Ashtari M, Zhang H, Cook PA, et al: Plasticity of the human visual system after retinal gene therapy in patients with Leber's congenital amaurosis. *Sci Transl Med* 7:296ra110, 2015

## Get the *Managing the Cost of Cancer Care* Booklets for Your Practice



Do your patients have financial questions about cancer care? Cancer.Net's *Managing the Cost of Cancer Care* booklet provides tools and resources that can help your patients answer these questions and plan for costs before, during, and after treatment. Order copies of the booklet for your patients through the ASCO University Bookstore at [www.cancer.net/estore](http://www.cancer.net/estore). ASCO members receive a 20% discount. The booklet is also available as a downloadable PDF in English and Spanish at [cancer.net/managingcostofcare](http://cancer.net/managingcostofcare).

ASCO<sup>®</sup>  
American Society of Clinical Oncology

**AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

**Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome**

*The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [jco.ascopubs.org/site/ifc](http://jco.ascopubs.org/site/ifc).*

**Sarah M. Nielsen**

No relationship to disclose

**Lindsay Rhodes**

**Employment:** GeneDx, BioReference

**Ignacio Blanco**

**Consulting or Advisory Role:** AstraZeneca

**Wendy K. Chung**

**Consulting or Advisory Role:** BioReference Laboratories

**Charis Eng**

**Consulting or Advisory Role:** N-of-One

**Eamonn R. Maher**

No relationship to disclose

**Stéphane Richard**

No relationship to disclose

**Rachel H. Giles**

No relationship to disclose

***Acknowledgment***

We dedicate this review to all our patients and their families and their multidisciplinary caregivers and researchers. We also thank the VHL Alliance, particularly Ilene Sussman and Eric Jonasch, for suggesting this collaboration and supporting our efforts. C.E. is the Sondra J. and Stephen R. Hardis Endowed Chair of Cancer Genomic Medicine at the Cleveland Clinic, and an American Cancer Society Clinical Research Professor. R.H.G. acknowledges the Dutch Kidney Foundation “KOUNCIL” consortium (CP11.13).